Shooting Cancer

18 07, 2022

Monthly focus on regulatory status of new targeted therapies in oncology – June 2022

adlitterio663392022-07-18T11:33:44+02:00

14 07, 2022

Monthly focus on regulatory status of new targeted therapies in oncology – June 2022

adlitterio663392022-07-14T13:59:36+02:00

20 05, 2022

Monthly focus on regulatory status of new targeted therapies in oncology – April 2022

Diatech Pharmacogenetics2022-05-20T11:09:53+02:00

12 04, 2022

Monthly focus on regulatory status of new targeted therapies in oncology- March 2022

Diatech Pharmacogenetics2022-04-12T17:26:35+02:00

12 04, 2022

ALK rearrangements: a biomarker at the forefront of NSCLC treatment

Diatech Pharmacogenetics2022-04-12T12:18:29+02:00

17 03, 2022

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology February 2022

Diatech Pharmacogenetics2022-03-17T17:35:47+01:00

23 02, 2022

Monthly focus on regulatory status of new targeted therapies in oncology- January 2022

Diatech Pharmacogenetics2022-04-12T17:30:48+02:00

26 01, 2022

Monthly focus on regulatory status of new targeted therapies in oncology- December 2021

Diatech Pharmacogenetics2022-01-27T17:31:38+01:00

21 12, 2021

Shooting Cancer – Highlights Monthly focus on regulatory status of new targeted therapies in oncology – November 2021

Diatech Pharmacogenetics2021-12-21T17:19:16+01:00

9 11, 2021

NTRK inhibitors, a successful example of a tissue-agnostic approach in anticancer targeted therapy

Diatech Pharmacogenetics2021-11-09T17:01:50+01:00

Vorheriges 234 Nächstes